<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>6545712</identifier>
<setSpec>0482-640X</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Hurtado Ruano, T</dc:author>
<dc:description xml:lang="en">A revision of the most promising clinical assays suggest that immunotherapy is useful for a certain number of selected patients. Immunotherapy cannot be used alone for primary treatment of cancer, excepting perhaps as local immunotherapy for readily accessible tumors. The most important role of immunotherapy is to be found in combination with other kinds of therapy, considering that it may restrain effectively hidden micrometastases that are the cause of relapse and fatal outcome. However, it is necessary to recognize that immunotherapy has shown until now a limited therapeutic efficacy.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:date>1984 </dc:date>
<dc:title xml:lang="es">Inmunoterapia oncol√≥gica.</dc:title>
<dc:title xml:lang="en">[Cancer immunotherapy].</dc:title>
<dc:publisher>Revista espanola de oncologia</dc:publisher>
</metadata>
</record>
</pubmed-document>
